World Journal of Urology

, Volume 19, Issue 5, pp 299–306

Which muscarinic receptor is important in the bladder?

  • T. Yamanishi
  • C. R. Chapple
  • R. Chess-Williams
TOPIC PAPER

DOI: 10.1007/s003450100226

Cite this article as:
Yamanishi, T., Chapple, C. & Chess-Williams, R. World J Urol (2001) 19: 299. doi:10.1007/s003450100226

Abstract

Antimuscarinic agents are the most widely used therapy for urge incontinence, but have side effects such as constipation, tachycardia and dry mouth, resulting from a lack of selectivity for the bladder. M2 receptors are the predominant cholinoceptors present in urinary bladder, but mainly the minor population of M3 receptors mediate its contraction. M2 receptors modulate detrusor contraction by several mechanisms, and may contribute more to contraction of the bladder in pathological states such as bladder denervation or spinal cord injury. Prejunctional inhibitory M2 or M4 receptors and prejunctional facilitatory muscarinic M1 receptors in the bladder have all been reported. In clinical studies, tolterodine, a non-selective muscarinic antagonist, has been reported to be as effective as oxybutynin but inducing less dry mouth. Thus, although it is not certain which antimuscarinic drugs have the better efficacy and tolerability, the non-selective antimuscarinic drugs seem to be better than M3-selective antagonists in their clinical efficacies. However, controlled release, or intravesical, intravaginal, or rectal administrations of oxybutynin have been reported to cause fewer side effects. Darifenacin, a new M3 selective antagonist, has been reported to have selectivity for the bladder over the salivary gland in vivo. To verify which antimuscarinic drugs selective for the muscarinic subtypes have the best efficacy and tolerability, comparative clinical trials between M3 selective antagonists and non-selective compounds, such as olterodine, are required in the future.

Key words muscarinic receptor urinary bladder urinary incontinence therapy 

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • T. Yamanishi
    • 1
  • C. R. Chapple
    • 2
  • R. Chess-Williams
    • 3
  1. 1.Department of Urology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba city, Chiba 260, JapanJP
  2. 2.Urology Research, J Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK e-mail: c.r.chapple@shef.ac.uk Tel.: +44-114-2712559; Fax: +44-114-2798318GB
  3. 3.Department of Urology, Royal Hallamshire Hospital, and Department of Biomedical Science, University of Sheffield, UKGB

Personalised recommendations